News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,064 Results
Type
Article (219)
Company Profile (63)
Press Release (7782)
Section
Business (4266)
Career Advice (8)
Deals (588)
Drug Development (419)
FDA (111)
Job Trends (206)
News (5083)
Policy (185)
Tag
2027 Biotech Bay Standard (1)
Academia (7)
Allergies (3)
Alliances (200)
Alzheimer's disease (7)
Antibody-drug conjugate (ADC) (1)
Approvals (113)
Artificial intelligence (6)
Autoimmune disease (1)
Bankruptcy (3)
Best Places to Work (204)
Biosimilars (1)
Biotechnology (45)
Bladder cancer (1)
Breast cancer (2)
Cancer (28)
Career advice (8)
Cell therapy (1)
Clinical research (377)
Collaboration (5)
Compensation (6)
COVID-19 (12)
C-suite (2)
Cystic fibrosis (9)
Data (50)
Depression (2)
Diabetes (4)
Diagnostics (127)
Digital health (1)
Drug discovery (5)
Drug pricing (1)
Duchenne muscular dystrophy (1)
Earnings (4346)
Events (973)
Executive appointments (3)
FDA (172)
Fibrodysplasia Ossificans Progressiva (1)
Funding (8)
Gene editing (3)
Gene therapy (4)
GLP-1 (6)
Government (12)
Guidances (52)
Healthcare (278)
HIV (3)
IgA nephropathy (1)
Immunology and inflammation (4)
Indications (1)
Infectious disease (14)
Inflammatory bowel disease (3)
Intellectual property (2)
Interviews (1)
IPO (417)
Job creations (20)
Job search strategy (7)
Layoffs (4)
Legal (29)
Lung cancer (8)
Lymphoma (3)
Machine learning (1)
Manufacturing (4)
MASH (4)
Medical device (249)
Medtech (251)
Mergers & acquisitions (177)
Metabolic disorders (11)
mRNA (5)
Multiple sclerosis (2)
Neurodegenerative disease (3)
Neuropsychiatric disorders (3)
Neuroscience (17)
NextGen: Class of 2026 (104)
Non-profit (22)
Obesity (3)
Pain (1)
Parkinson's disease (4)
Patents (4)
Peanut (1)
People (173)
Pharmaceutical (8)
Phase 1 (84)
Phase 2 (158)
Phase 3 (168)
Pipeline (227)
Policy (2)
Postmarket research (13)
Preclinical (33)
Prostate cancer (1)
Radiopharmaceuticals (1)
Rare diseases (13)
Real estate (29)
Regulatory (161)
Reports (1)
Research institute (13)
RSV (2)
Service/supplier (1)
Sickle cell disease (3)
Spinal muscular atrophy (4)
Sponsored (1)
Startups (14)
Tariffs (1)
Vaccines (17)
Weight loss (1)
Women's health (3)
Date
Today (2)
Last 7 days (13)
Last 30 days (65)
Last 365 days (470)
2026 (86)
2025 (467)
2024 (627)
2023 (700)
2022 (780)
2021 (672)
2020 (653)
2019 (481)
2018 (452)
2017 (353)
2016 (238)
2015 (314)
2014 (214)
2013 (165)
2012 (203)
2011 (182)
2010 (172)
Location
Africa (10)
Alabama (1)
Arizona (5)
Asia (336)
Australia (57)
California (253)
Canada (39)
China (10)
Colorado (10)
Connecticut (4)
Delaware (4)
Europe (777)
Florida (24)
Georgia (4)
Idaho (1)
Illinois (21)
India (1)
Indiana (14)
Kansas (2)
Kentucky (3)
Louisiana (5)
Maine (3)
Maryland (19)
Massachusetts (108)
Michigan (6)
Minnesota (21)
Missouri (1)
Montana (2)
Nevada (1)
New Hampshire (2)
New Jersey (81)
New York (50)
North Carolina (26)
Northern California (97)
Ohio (4)
Oregon (2)
Pennsylvania (40)
South America (16)
Southern California (94)
Tennessee (4)
Texas (18)
United States (747)
Utah (8)
Virginia (1)
Washington D.C. (2)
Washington State (15)
Wisconsin (1)
8,064 Results for "940".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
January 20, 2026
·
6 min read
Press Releases
U.S. DNA Sequencing Market Size to Achieve USD 18,940 Million by 2034
February 25, 2025
·
1 min read
Business
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Merck & Co. and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157).
December 11, 2023
·
56 min read
Business
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)
Moderna, Inc. and Merck today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT).
June 5, 2023
·
54 min read
Drug Development
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Merck, known as MSD outside of the United States and Canada, and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk melanoma.
July 26, 2023
·
51 min read
Business
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)
Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study.
June 3, 2024
·
60 min read
Genetown
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
Moderna, Inc. today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL.
May 30, 2023
·
5 min read
Press Releases
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
October 28, 2024
·
19 min read
Drug Development
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL.
March 14, 2023
·
5 min read
Policy
MRNA-4157/V940 in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the EMA for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. and Merck announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, has been granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.
April 6, 2023
·
49 min read
1 of 807
Next
